Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens: a markov model
Future first-line tuberculosis treatment may include fluoroquinolones and/or require testing for fluoroquinolone susceptibility. We use a quantitative model to
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1 December 2020
|
| In: |
Clinical infectious diseases
Year: 2020, Jahrgang: 71, Heft: 11, Pages: 2889-2896 |
| ISSN: | 1537-6591 |
| DOI: | 10.1093/cid/ciz1179 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/cid/ciz1179 Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/cid/article/doi/10.1093/cid/ciz1179/5669959 
|
| Verfasserangaben: | Emily A. Kendall, Shelly Malhotra, Sarah Cook-Scalise, David W. Dowdy, Claudia M. Denkinger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1725068214 | ||
| 003 | DE-627 | ||
| 005 | 20230426103332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200717s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciz1179 |2 doi | |
| 035 | |a (DE-627)1725068214 | ||
| 035 | |a (DE-599)KXP1725068214 | ||
| 035 | |a (OCoLC)1341346955 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kendall, Emily A. |e VerfasserIn |0 (DE-588)1207414751 |0 (DE-627)1693718685 |4 aut | |
| 245 | 1 | 0 | |a Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens |b a markov model |c Emily A. Kendall, Shelly Malhotra, Sarah Cook-Scalise, David W. Dowdy, Claudia M. Denkinger |
| 264 | 1 | |c 1 December 2020 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online December 9, 2019 | ||
| 500 | |a Gesehen am 17.07.2020 | ||
| 520 | |a Future first-line tuberculosis treatment may include fluoroquinolones and/or require testing for fluoroquinolone susceptibility. We use a quantitative model to | ||
| 700 | 1 | |a Malhotra, Shelly |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cook-Scalise, Sarah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dowdy, David W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Denkinger, Claudia M. |d 1978- |e VerfasserIn |0 (DE-588)131597701 |0 (DE-627)511279469 |0 (DE-576)298613727 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases |d Oxford : Oxford Journals, 1992 |g 71(2020), 11 vom: Dez., Seite 2889-2896 |h Online-Ressource |w (DE-627)320418308 |w (DE-600)2002229-3 |w (DE-576)090881834 |x 1537-6591 |7 nnas |a Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens a markov model |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:11 |g month:12 |g pages:2889-2896 |g extent:8 |a Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens a markov model |
| 856 | 4 | 0 | |u https://doi.org/10.1093/cid/ciz1179 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/cid/article/doi/10.1093/cid/ciz1179/5669959 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200717 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 131597701 |a Denkinger, Claudia M. |m 131597701:Denkinger, Claudia M. |d 910000 |d 911700 |d 50000 |e 910000PD131597701 |e 911700PD131597701 |e 50000PD131597701 |k 0/910000/ |k 1/910000/911700/ |k 0/50000/ |p 5 |y j | ||
| 999 | |a KXP-PPN1725068214 |e 3725460353 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1725068214","physDesc":[{"extent":"8 S."}],"title":[{"title":"Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens","title_sort":"Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens","subtitle":"a markov model"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Published online December 9, 2019","Gesehen am 17.07.2020"],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"1 December 2020"}],"person":[{"display":"Kendall, Emily A.","given":"Emily A.","role":"aut","family":"Kendall"},{"family":"Malhotra","role":"aut","given":"Shelly","display":"Malhotra, Shelly"},{"given":"Sarah","role":"aut","family":"Cook-Scalise","display":"Cook-Scalise, Sarah"},{"role":"aut","given":"David W.","family":"Dowdy","display":"Dowdy, David W."},{"display":"Denkinger, Claudia M.","family":"Denkinger","role":"aut","given":"Claudia M."}],"relHost":[{"origin":[{"dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisherPlace":"Oxford ; Chicago, Ill.","publisher":"Oxford Journals ; Univ. of Chicago Press, Journals Division"}],"pubHistory":["14.1992 -"],"id":{"zdb":["2002229-3"],"issn":["1537-6591"],"eki":["320418308"]},"title":[{"title_sort":"Clinical infectious diseases","title":"Clinical infectious diseases","subtitle":"electronic edition"}],"part":{"volume":"71","year":"2020","issue":"11","extent":"8","text":"71(2020), 11 vom: Dez., Seite 2889-2896","pages":"2889-2896"},"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 31.07.2023"],"recId":"320418308","physDesc":[{"extent":"Online-Ressource"}],"disp":"Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens a markov modelClinical infectious diseases"}],"id":{"eki":["1725068214"],"doi":["10.1093/cid/ciz1179"]},"name":{"displayForm":["Emily A. Kendall, Shelly Malhotra, Sarah Cook-Scalise, David W. Dowdy, Claudia M. Denkinger"]}} | ||
| SRT | |a KENDALLEMICLINICALIM1202 | ||